BIIB
Price
$132.63
Change
+$1.65 (+1.26%)
Updated
Jul 24, 04:59 PM (EDT)
Capitalization
31.34B
7 days until earnings call
HBIO
Price
$0.58
Change
+$0.02 (+3.57%)
Updated
Jul 24, 04:59 PM (EDT)
Capitalization
184.01M
13 days until earnings call
Interact to see
Advertisement

BIIB vs HBIO

Header iconBIIB vs HBIO Comparison
Open Charts BIIB vs HBIOBanner chart's image
Biogen
Price$132.63
Change+$1.65 (+1.26%)
Volume$46.81K
Capitalization31.34B
Harvard Bioscience
Price$0.58
Change+$0.02 (+3.57%)
Volume$1.85K
Capitalization184.01M
BIIB vs HBIO Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS), Exelixis (NASDAQ:EXEL).

Industry description

Few industries pique investor interest like the high-risk, high-reward biotechnology sector. It is not unusual for a biotech company’s stock to soar in value following the development of a successful product...even if it is just as likely that tens of millions of dollars in research will lead to nothing substantial. Biotech companies earn headlines for developing lifesaving and (potentially) massively lucrative treatments for illness, but the industry’s scope extends beyond healthcare to food and agriculture, industrial processing, and more. Any company producing technology that incorporates biological organisms falls within the sector. The search for the next big thing in biotech may come with risk, but investors have reason for optimism. Biotech products like DNA sequencing and gene therapy are experiencing increased demand and decreasing prices, while rising populations around the world mean demand for food and agricultural products resistant to environmental factors. Biotech’s biggest names include multinational corporations like Johnson & Johnson, Amgen, and Roche, who each sport market capitalizations in the hundreds of billions of dollars. With new government rules opening China as a market for new treatments, the biotech sector holds significant growth potential – and corresponding profitability for investors.

Market Cap

The average market capitalization across the biotechnology Theme is 7.03B. The market cap for tickers in the group ranges from 658 to 220.19B. TMO holds the highest valuation in this group at 220.19B. The lowest valued company is MTEM at 658.

High and low price notable news

The average weekly price growth across all stocks in the biotechnology Theme was 3%. For the same Theme, the average monthly price growth was 14%, and the average quarterly price growth was 23%. IOVA experienced the highest price growth at 78%, while REPL experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the biotechnology Theme was 36%. For the same stocks of the Theme, the average monthly volume growth was 52% and the average quarterly volume growth was 114%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 76
Price Growth Rating: 56
SMR Rating: 88
Profit Risk Rating: 90
Seasonality Score: -5 (-100 ... +100)

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB).

Market Cap

The average market capitalization across the group is 15.76B. The market cap for tickers in the group ranges from 184.01M to 31.34B. BIIB holds the highest valuation in this group at 31.34B. The lowest valued company is HBIO at 184.01M.

High and low price notable news

The average weekly price growth across all stocks in the group was 20%. For the same group, the average monthly price growth was 7%, and the average quarterly price growth was -39%. HBIO experienced the highest price growth at 37%, while BIIB experienced the biggest fall at 2%.

Volume

The average weekly volume growth across all stocks in the group was 107%. For the same stocks of the group, the average monthly volume growth was 91% and the average quarterly volume growth was 235%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 94
P/E Growth Rating: 49
Price Growth Rating: 63
SMR Rating: 85
Profit Risk Rating: 100
Seasonality Score: -50 (-100 ... +100)
VS
BIIB vs. HBIO commentary
Jul 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongBuy and HBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 25, 2025
Stock price -- (BIIB: $130.98 vs. HBIO: $0.56)
Brand notoriety: BIIB: Notable vs. HBIO: Not notable
BIIB represents the Pharmaceuticals: Major, while HBIO is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BIIB: 81% vs. HBIO: 15%
Market capitalization -- BIIB: $31.34B vs. HBIO: $184.01M
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. HBIO’s [@Medical Specialties] market capitalization is $184.01M. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B. The average market capitalization across the [@Medical Specialties] industry is $8.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileHBIO’s FA Score has 1 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • HBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, HBIO is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while HBIO’s TA Score has 6 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 3 bearish.
  • HBIO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, HBIO is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +1.96% price change this week, while HBIO (@Medical Specialties) price change was +37.23% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.31%. For the same industry, the average monthly price growth was +5.85%, and the average quarterly price growth was +12.45%.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.09%. For the same industry, the average monthly price growth was +4.90%, and the average quarterly price growth was -2.19%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

HBIO is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+3.31% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Medical Specialties (+3.09% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIIB($31.3B) has a higher market cap than HBIO($184M). BIIB YTD gains are higher at: -14.347 vs. HBIO (-73.659). BIIB has higher annual earnings (EBITDA): 2.04B vs. HBIO (8.03M). BIIB has more cash in the bank: 1.05B vs. HBIO (4.28M). HBIO has less debt than BIIB: HBIO (42.8M) vs BIIB (7.34B). BIIB has higher revenues than HBIO: BIIB (9.84B) vs HBIO (112M).
BIIBHBIOBIIB / HBIO
Capitalization31.3B184M17,011%
EBITDA2.04B8.03M25,370%
Gain YTD-14.347-73.65919%
P/E Ratio26.95N/A-
Revenue9.84B112M8,782%
Total Cash1.05B4.28M24,516%
Total Debt7.34B42.8M17,145%
FUNDAMENTALS RATINGS
BIIB vs HBIO: Fundamental Ratings
BIIB
HBIO
OUTLOOK RATING
1..100
6255
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7299
PRICE GROWTH RATING
1..100
6265
P/E GROWTH RATING
1..100
962
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIIB's Valuation (88) in the Biotechnology industry is in the same range as HBIO (100). This means that BIIB’s stock grew similarly to HBIO’s over the last 12 months.

BIIB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as HBIO (100). This means that BIIB’s stock grew similarly to HBIO’s over the last 12 months.

BIIB's SMR Rating (72) in the Biotechnology industry is in the same range as HBIO (99). This means that BIIB’s stock grew similarly to HBIO’s over the last 12 months.

BIIB's Price Growth Rating (62) in the Biotechnology industry is in the same range as HBIO (65). This means that BIIB’s stock grew similarly to HBIO’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for BIIB (96). This means that HBIO’s stock grew significantly faster than BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBHBIO
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
51%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 8 days ago
73%
Declines
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
57%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LQRCF1.540.14
+10.07%
Black Mammoth Metals Corp
EBCOF15.53N/A
N/A
Ebara Corp.
NPCPF8.12N/A
N/A
Nippon Paint Holdings Co., Ltd.
BKFL14.00N/A
N/A
BankFlorida Bancorp, Inc.
LWSCF13.29-0.13
-0.94%
Sienna Sr Living Inc.

BIIB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+2.45%
AMGN - BIIB
58%
Loosely correlated
+1.15%
PFE - BIIB
53%
Loosely correlated
+0.88%
SNY - BIIB
47%
Loosely correlated
+2.89%
MRK - BIIB
46%
Loosely correlated
+2.90%
NVS - BIIB
45%
Loosely correlated
+0.98%
More

HBIO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
+25.46%
IRMD - HBIO
51%
Loosely correlated
+1.24%
A - HBIO
37%
Loosely correlated
+2.82%
ICUI - HBIO
36%
Loosely correlated
+2.19%
ANGO - HBIO
35%
Loosely correlated
+0.88%
MTD - HBIO
35%
Loosely correlated
+3.14%
More